MVA-mBN226B
- Generic Name
- MVA-mBN226B
- Drug Type
- Biotech
Ad26.ZEBOV, MVA-BN-Filo Vaccination in Children and Adults Previously Vaccinated With Control in the EBOVAC-Salone Study
Phase 2
Completed
- Conditions
- Virus DiseasesHemorrhagic Fevers, ViralHemorrhagic Fever, EbolaRNA Virus InfectionsFiloviridae InfectionsImmunologic FactorsPhysiological Effects of DrugsEbolaInfectionsMononegavirales Infections
- Interventions
- First Posted Date
- 2022-03-17
- Last Posted Date
- 2025-05-11
- Lead Sponsor
- London School of Hygiene and Tropical Medicine
- Target Recruit Count
- 133
- Registration Number
- NCT05284097
- Locations
- πΈπ±
EBOVAC Kambia 1 clinic, Kambia, Sierra Leone
A Study of a 2-dose Ebola Vaccine Regimen of Ad26.ZEBOV Followed by MVA-BN-Filo in Healthy Pregnant Women
- First Posted Date
- 2020-09-21
- Last Posted Date
- 2025-02-03
- Lead Sponsor
- Janssen Vaccines & Prevention B.V.
- Target Recruit Count
- 4031
- Registration Number
- NCT04556526
- Locations
- π·πΌ
Gisenyi Hospital, Gysenyi, Rwanda
π·πΌGihundwe District Hospital, Cuangugu, Rwanda
π·πΌCenter for Family Health Research/Project San Francisco, Kigali, Rwanda
A Study of 2-dose Vaccine Regimen Using 3 Consecutive Lots of Ad26.ZEBOV and MVA-BN-Filo in Adult Participants
Phase 3
Completed
- Conditions
- Ebola
- Interventions
- First Posted Date
- 2020-01-14
- Last Posted Date
- 2025-04-27
- Lead Sponsor
- Janssen Vaccines & Prevention B.V.
- Target Recruit Count
- 974
- Registration Number
- NCT04228783
- Locations
- πΊπΈ
Clinical Research Consortium, an AMR company, Las Vegas, Nevada, United States
πΊπΈCoastal Clinical Research, Inc, Mobile, Alabama, United States
πΊπΈCentral Kentucky Research Associates, Inc., Lexington, Kentucky, United States
A Study of 2-dose Vaccination Regimen of Ad26.ZEBOV and MVA-BN-Filo in Infants
Phase 2
Completed
- Conditions
- Ebola Virus Disease
- Interventions
- First Posted Date
- 2019-04-29
- Last Posted Date
- 2025-04-27
- Lead Sponsor
- Janssen Vaccines & Prevention B.V.
- Target Recruit Count
- 108
- Registration Number
- NCT03929757
- Locations
- π¬π³
Centre National de Formation et de Recherche en Sante Rurale de Maferinyah, Conakry, Guinea
πΈπ±College of Med and Allied Health Sciences, University of Sierra Leone, Freetown, Sierra Leone
Safety, Tolerability and Immunogenicity Study of 2-dose Heterologous Regimens for Ebola Vaccines Ad26.ZEBOV/MVA-BN-Filo
Phase 2
Completed
- Conditions
- Hemorrhagic Fever, Ebola
- Interventions
- First Posted Date
- 2015-11-05
- Last Posted Date
- 2025-02-04
- Lead Sponsor
- Janssen Vaccines & Prevention B.V.
- Target Recruit Count
- 578
- Registration Number
- NCT02598388
A Study to Evaluate the Immunogenicity, Safety and Tolerability of Ad26.ZEBOV and MVA-BN-Filo in Healthy Adult Participants
Phase 3
Completed
- Conditions
- Healthy
- Interventions
- Biological: Ad26.ZEBOV-Batch #1Biological: Ad26.ZEBOV-Batch #2Biological: Ad26.ZEBOV-Batch #3Biological: Placebo
- First Posted Date
- 2015-09-07
- Last Posted Date
- 2025-04-27
- Lead Sponsor
- Crucell Holland BV
- Target Recruit Count
- 329
- Registration Number
- NCT02543268
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
Β© Copyright 2025. All Rights Reserved by MedPath